Personalis, Inc. (PSNL): R&D Expense
$50.26M
Year ended 2025-12-31
$56.12M
Trailing 12 months to 2026-06-30
-8.2%
3-year compound annual growth
+12.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.26M | +2.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $48.91M | -24.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $64.78M | -0.2% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $64.91M | +31.6% | 2024-02-28, From 2022-01-01 |
| 2021-12-31 | $49.31M | +72.6% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $28.57M | +27.4% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $22.42M | +56.7% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $14.30M | +44.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $9.92M | n/a | 2020-03-25, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Personalis, Inc. (PSNL) | 2025-12-31 | $50.26M | +2.8% |
| Exagen Inc. (XGN) | 2025-12-31 | $6.25M | +16.4% |
| Biodesix Inc (BDSX) | 2025-12-31 | $12.00M | +25.5% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
Compare PSNL, XGN, BDSX, GRAL side by side · Screen every company in Services-Medical Laboratories ↗